Checkpoint Kinase (Chk) Inhibitor

Checkpoint Kinase (Chk) Inhibitors (30):

Cat. No.	Product Name	Effect	Purity

HY-P99032

Monalizumab	Inhibitor	99.69%
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

HY-148962

LY2880070	Inhibitor	99.9%
LY2880070 is an orally active CHK1 inhibitor, IC₅₀ ＜ 1 nM. LY2880070 can be used as an anticancer agent for combination with DNA damaging agents.

HY-112167

GDC-0575	Inhibitor	99.68%
GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC₅₀ of 1.2 nM.

HY-100341

M2I-1	Inhibitor	98.0%
M2I-1 is a Mad2 inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the spindle assembly checkpoint (SAC).

HY-180357

Graviquinone	Inhibitor
Graviquinone is a Chk1 inhibitor. Graviquinone exhibits potent cytotoxicity against various cancer cell lines. Graviquinone possesses the characteristics of bypassing ABCB1-mediated multidrug resistance, selectively damaging cancer cell DNA, and regulating the DNA damage response. Graviquinone can also enhance cytotoxicity by increasing ROS levels in cancer cells. Graviquinone can be used for cancer research.

HY-122198

ML367	Inhibitor	99.84%
ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization, acts as a probe molecule that has low micromolar inhibitory activity. ML367 blocks DNA repair pathways, suppresses general DNA damage responses including RPA32-phosphorylation and CHK1-phosphorylation in response to UV irradiation.

HY-RS02616

CHEK1 Human Pre-designed siRNA Set A	Inhibitor
CHEK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CHEK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-103367

CHK1-IN-7	Inhibitor	≥98.0%
CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer.

HY-161622

K1586	Inhibitor	99.63%
K1586 is an amidine derivative that efficiently targets Chk1. K1586 enhances the degradation of Chk1 that sensitizes colorectal cancer cells to ionizing radiation. K1586 shows anticancer effects.

HY-112927

MU380	Inhibitor	99.6%
MU380 is a potent and selective CHK1 inhibitor that induces apoptosis and has anticancer activity.

HY-47026

Protein kinase inhibitor 6	Inhibitor	99.04%
Protein kinase inhibitor 6 is a protein kinase inhibitor.

HY-P991058

Zimistobart	Inhibitor
Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-123597

NSC 109555	Inhibitor
NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC₅₀=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC₅₀ values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC₅₀=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.

HY-RS02618

Chek1 Rat Pre-designed siRNA Set A	Inhibitor
Chek1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Chek1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-119699

PV1115	Inhibitor
PV1115 is a potent and highly selective Chk2 inhibitor with an IC₅₀ of 0.14 nM, 66000 nM, >100000 nM for Chk2, Chk1 and RSK2, respectively. PV1115 is situated within the ATP-binding pocket of Chk2.

HY-RS02619

CHEK2 Human Pre-designed siRNA Set A	Inhibitor
CHEK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CHEK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02620

Chek2 Mouse Pre-designed siRNA Set A	Inhibitor
Chek2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Chek2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02621

Chek2 Rat Pre-designed siRNA Set A	Inhibitor
Chek2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Chek2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-124122

BPTQ	Inhibitor
BPTQ is a potent inhibitor against VEGFR1 and CHK2 with IC₅₀ values of 0.54 and 1.70 µmol/L, respectively. BPTQ is also an intercalator of DNA with anticancer activities. BPTQ inhibits the proliferation of HL-60 cells by arresting cells at S and G2/M phase with an IC₅₀ value of 12 µmol/L. BPTQ also activates the mitochondria-mediated Apoptosis pathway by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio and activation of caspases.

HY-P4978

CBP501 Affinity Peptide	Inhibitor
CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. CBP501 Affinity Peptide can be used in cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.